Recursion Pharmaceuticals, Inc. Files Definitive Proxy Statement

Ticker: RXRX · Form: DEF 14A · Filed: Apr 23, 2024 · CIK: 1601830

Recursion Pharmaceuticals, Inc. DEF 14A Filing Summary
FieldDetail
CompanyRecursion Pharmaceuticals, Inc. (RXRX)
Form TypeDEF 14A
Filed DateApr 23, 2024
Risk Levellow
Pages16
Reading Time19 min
Key Dollar Amounts$50 million, $100B
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Executive Compensation, Equity Awards, Recursion Pharmaceuticals

TL;DR

<b>Recursion Pharmaceuticals filed its DEF 14A, detailing executive compensation and equity awards for 2021-2023.</b>

AI Summary

RECURSION PHARMACEUTICALS, INC. (RXRX) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Recursion Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 23, 2024. The filing covers the period ending June 3, 2024, with data as of April 23, 2024. The company's fiscal year ends on December 31st. The filing includes details on equity awards granted to both principal executive officers (PEO) and non-PEO/NEO members for the fiscal years 2021, 2022, and 2023. Specific data points include the year-end fair value of outstanding and unvested equity awards, changes in fair value, and visiting date fair values.

Why It Matters

For investors and stakeholders tracking RECURSION PHARMACEUTICALS, INC., this filing contains several important signals. This filing provides transparency into the company's executive compensation structure and the valuation of equity awards, which is crucial for shareholder understanding and governance. The detailed breakdown of equity awards for PEO and non-PEO/NEO members allows investors to assess how compensation aligns with company performance and strategic objectives.

Risk Assessment

Risk Level: low — RECURSION PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and equity awards, with no immediate red flags or significant new information that would alter the risk profile.

Analyst Insight

Review the detailed breakdown of equity awards and their valuation changes to understand executive compensation trends and potential impacts on shareholder value.

Key Numbers

  • 2024-04-23 — Filing Date (DEF 14A filing date)
  • 2024-06-03 — Period of Report (Conformed period of report)
  • 2023-12-31 — Fiscal Year End (Company's fiscal year end)
  • 2021-01-01 — Data Start Date (Start date for equity award data)
  • 2023-12-31 — Data End Date (End date for equity award data)

Key Players & Entities

  • Recursion Pharmaceuticals, Inc. (company) — Filer
  • 41S RIO GRANDE STREET (address) — Business and Mail Address
  • SALT LAKE CITY (location) — Business and Mail City
  • UT (location) — Business and Mail State
  • DE (location) — State of Incorporation

FAQ

When did RECURSION PHARMACEUTICALS, INC. file this DEF 14A?

RECURSION PHARMACEUTICALS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 23, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by RECURSION PHARMACEUTICALS, INC. (RXRX).

Where can I read the original DEF 14A filing from RECURSION PHARMACEUTICALS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by RECURSION PHARMACEUTICALS, INC..

What are the key takeaways from RECURSION PHARMACEUTICALS, INC.'s DEF 14A?

RECURSION PHARMACEUTICALS, INC. filed this DEF 14A on April 23, 2024. Key takeaways: Recursion Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 23, 2024.. The filing covers the period ending June 3, 2024, with data as of April 23, 2024.. The company's fiscal year ends on December 31st..

Is RECURSION PHARMACEUTICALS, INC. a risky investment based on this filing?

Based on this DEF 14A, RECURSION PHARMACEUTICALS, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and equity awards, with no immediate red flags or significant new information that would alter the risk profile.

What should investors do after reading RECURSION PHARMACEUTICALS, INC.'s DEF 14A?

Review the detailed breakdown of equity awards and their valuation changes to understand executive compensation trends and potential impacts on shareholder value. The overall sentiment from this filing is neutral.

How does RECURSION PHARMACEUTICALS, INC. compare to its industry peers?

Recursion Pharmaceuticals operates in the biotechnology sector, focusing on drug discovery and development using artificial intelligence and machine learning.

Are there regulatory concerns for RECURSION PHARMACEUTICALS, INC.?

This filing is a standard DEF 14A, required by the SEC for public companies to disclose information related to shareholder meetings, including executive compensation.

Industry Context

Recursion Pharmaceuticals operates in the biotechnology sector, focusing on drug discovery and development using artificial intelligence and machine learning.

Regulatory Implications

This filing is a standard DEF 14A, required by the SEC for public companies to disclose information related to shareholder meetings, including executive compensation.

What Investors Should Do

  1. Analyze the fair value changes of equity awards for PEOs and non-PEOs/NEOs across 2021-2023.
  2. Examine the vesting schedules and conditions associated with the granted equity awards.
  3. Compare the executive compensation disclosures with industry benchmarks if available.

Year-Over-Year Comparison

This filing is a routine DEF 14A, providing updated information on executive compensation and equity awards compared to previous periods.

Filing Stats: 4,724 words · 19 min read · ~16 pages · Grade level 16 · Accepted 2024-04-23 17:15:42

Key Financial Figures

  • $50 million — atform) – additionally, NVIDIA invested $50 million in Recursion via a private placement E
  • $100B — ompanies with market caps solidly above $100B as of writing this note). As such, we w

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 33

EXECUTIVE COMPENSATION TABLES

EXECUTIVE COMPENSATION TABLES 46 REPORT OF THE AUDIT COMMITTEE 58 EXECUTIVE OFFICERS 60 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 62

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 63 DELINQUENT SECTION 16( a ) REPORTS 66 HOUSEHOLDING 66 STOCKHOL

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.